← Browse by Condition

Medical Condition

hiv infections

Total Trials

21

Recruiting Now

21

Trial Phases

Phase 1, Phase 4

ClinicalMetric tracks all active clinical trials for hiv infections sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hiv infections Clinical Trials

How many clinical trials are currently recruiting for hiv infections?

ClinicalMetric currently tracks 21 actively recruiting clinical trials for hiv infections, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 21. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for hiv infections?

hiv infections research spans Phase 1 (2 trials), Phase 4 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a hiv infections clinical trial?

Eligibility criteria for hiv infections trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

2

Phase 4

2

Top Sponsors

Henry M. Jackson Foundation for the Advancement of Military Medicine 2 trials

Oswaldo Cruz Foundation 2 trials

Johns Hopkins University 2 trials

University of Zurich 1 trial

Guangzhou 8th People's Hospital 1 trial

Recruiting Clinical Trials

Characterization of Acute and Recent HIV-1 Infections in Zurich.

University of Zurich

NCT06484335 Phase 1

RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV

Henry M. Jackson Foundation fo...

Observational Study on Patients With HIV/AIDS(OSPWH)

Guangzhou 8th People's Hospita...

Improving HIV Testing, Linkage, and Retention in Care for Men Through U=U Messaging

Desmond Tutu HIV Foundation

NCT03132311 Phase 4

Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals

Oswaldo Cruz Foundation

Improving Access to PrEP (HIV Prevention Medication) for People in Underserved Areas of Rio de Janeiro

Oswaldo Cruz Foundation

Cohort Study of HIV-positive People, Treated With Long Acting Antiretroviral Therapy

Castagna Antonella

Skeletal Muscle Energetics and Fatiguability in Older Individuals

Johns Hopkins University

Development of a New Family of HIV Latency Regulators (LRAs) Targeting the Tat Viral Protein

University Hospital, Montpelli...

The TAIL-PrEP Study

Columbia University

Protocol RV 583 Multinational Observational Cohort of HIV and Other Infections

Kenya, Nigeria, Phil...

Henry M. Jackson Foundation fo...

Peer Behavioral Activation Utilization to Improve Substance Use and HIV Outcomes in People Receiving Long Acting Injectable-PrEP/ART (PUSH)

University of Maryland, Baltim...

South Africa Smoking Cessation and Engagement in HIV/TB Care Care

Massachusetts General Hospital

Study of Autophagy and the Effects of GALIG Gene Products in HIV-1 Infected Patients Who Are Under Antiretroviral Therapy Since Primary-infection, Chronic Phase, or Never Treated.

Centre Hospitalier Régional d'...

Comparing Mobile Health Strategies to Improve Pre-exposure Prophylaxis Use (PrEP) for HIV Prevention

Public Health Foundation Enter...

Alcohol Misuse, Gut Microbial Dysbiosis and PrEP Care Continuum: Application and Efficacy of SBIRT Intervention

Shirish S Barve

Microbiota Footprint and Frailty Phenotype in Virologically Suppressed People Living With HIV

Hôpital Européen Marseille

Syringe Service Based Telemedicine and Social Network Driven HIV Prevention Service Implementation

Johns Hopkins University

NCT07525544 Phase 1

A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants

ViiV Healthcare

Positive Peers Intervention Clinical Trial

MetroHealth Medical Center

NCT07138144 Phase 4

Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up

José Antonio Mata Marín

Related Conditions

plwh (1) art (1) acute hiv infection (1) men (1) treatment adherence (1) hiv (1) substance use (1) tuberculosis (1) smoking cessation (1) autophagy (1) galectins (1) highly active antiretroviral therapy (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology